JP7574204B2 - レボケトコナゾールによる疾患の処置方法 - Google Patents

レボケトコナゾールによる疾患の処置方法 Download PDF

Info

Publication number
JP7574204B2
JP7574204B2 JP2021552515A JP2021552515A JP7574204B2 JP 7574204 B2 JP7574204 B2 JP 7574204B2 JP 2021552515 A JP2021552515 A JP 2021552515A JP 2021552515 A JP2021552515 A JP 2021552515A JP 7574204 B2 JP7574204 B2 JP 7574204B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
pharma
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522873A5 (https=
JP2022522873A (ja
Inventor
コーエン，フレドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strongbridge Dublin Ltd
Original Assignee
Strongbridge Dublin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7574204(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strongbridge Dublin Ltd filed Critical Strongbridge Dublin Ltd
Publication of JP2022522873A publication Critical patent/JP2022522873A/ja
Publication of JP2022522873A5 publication Critical patent/JP2022522873A5/ja
Priority to JP2024180821A priority Critical patent/JP7801408B2/ja
Application granted granted Critical
Publication of JP7574204B2 publication Critical patent/JP7574204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021552515A 2019-03-04 2020-03-02 レボケトコナゾールによる疾患の処置方法 Active JP7574204B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180821A JP7801408B2 (ja) 2019-03-04 2024-10-16 レボケトコナゾールによる疾患の処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813399P 2019-03-04 2019-03-04
US62/813,399 2019-03-04
PCT/US2020/020644 WO2020180784A1 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180821A Division JP7801408B2 (ja) 2019-03-04 2024-10-16 レボケトコナゾールによる疾患の処置方法

Publications (3)

Publication Number Publication Date
JP2022522873A JP2022522873A (ja) 2022-04-20
JP2022522873A5 JP2022522873A5 (https=) 2023-03-09
JP7574204B2 true JP7574204B2 (ja) 2024-10-28

Family

ID=72338256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552515A Active JP7574204B2 (ja) 2019-03-04 2020-03-02 レボケトコナゾールによる疾患の処置方法
JP2024180821A Active JP7801408B2 (ja) 2019-03-04 2024-10-16 レボケトコナゾールによる疾患の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180821A Active JP7801408B2 (ja) 2019-03-04 2024-10-16 レボケトコナゾールによる疾患の処置方法

Country Status (10)

Country Link
US (5) US11020393B2 (https=)
EP (1) EP3934649A4 (https=)
JP (2) JP7574204B2 (https=)
KR (2) KR102950333B1 (https=)
CN (1) CN113710250A (https=)
AU (2) AU2020232246B2 (https=)
BR (1) BR112021017561A2 (https=)
CA (1) CA3132319A1 (https=)
IL (1) IL286099A (https=)
WO (1) WO2020180784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526830A (ja) 2005-01-10 2008-07-24 コーテンド インベスト アーベー （ピーユービーエル） 糖尿病、メタボリック症候群、および他の状態を治療するための方法および組成物
JP2010505866A (ja) 2006-10-02 2010-02-25 コルテンド・インヴェスト・アクチボラゲット ヒトにおけるケトコナゾールエナンチオマー
WO2016048984A1 (en) 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
US11261157B2 (en) * 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US10512667B2 (en) * 2017-06-27 2019-12-24 The Regents Of The University Of Michigan Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526830A (ja) 2005-01-10 2008-07-24 コーテンド インベスト アーベー （ピーユービーエル） 糖尿病、メタボリック症候群、および他の状態を治療するための方法および組成物
JP2010505866A (ja) 2006-10-02 2010-02-25 コルテンド・インヴェスト・アクチボラゲット ヒトにおけるケトコナゾールエナンチオマー
WO2016048984A1 (en) 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
US20180338971A1 (en) 2014-09-25 2018-11-29 Strongbridge Ireland Limited Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes，https://ichgcp.net/clinical-trials-registry/NCT00494663，インターネット［令和６年３月１３日検索］
Clinical Therapeutics，2008年，Vol.30(6)，pp.1081-1088
徹底マスター 薬の相互作用としくみ アンカートランスポーターMATEが関与する相互作用，2015年，https://medical.nikkeibp.co.jp/leaf/all/di/digital/201506/542488.html
研究課題名（和文）メタボリックシンドローム患者の薬物動態変動機構の解明と薬物治療への応用，科学研究費補助金研究成果報告書，2011年

Also Published As

Publication number Publication date
AU2025204382A1 (en) 2025-07-03
AU2020232246B2 (en) 2025-03-20
KR20260049881A (ko) 2026-04-14
US20200397781A1 (en) 2020-12-24
KR20210135278A (ko) 2021-11-12
US20240148724A1 (en) 2024-05-09
US11278547B2 (en) 2022-03-22
JP7801408B2 (ja) 2026-01-16
WO2020180784A1 (en) 2020-09-10
KR102950333B1 (ko) 2026-04-08
IL286099A (en) 2021-10-31
BR112021017561A2 (pt) 2021-11-09
US11020393B2 (en) 2021-06-01
JP2025026838A (ja) 2025-02-26
EP3934649A1 (en) 2022-01-12
US20210267970A1 (en) 2021-09-02
EP3934649A4 (en) 2022-11-23
US11903940B2 (en) 2024-02-20
US20220387425A1 (en) 2022-12-08
US20250387389A1 (en) 2025-12-25
CN113710250A (zh) 2021-11-26
JP2022522873A (ja) 2022-04-20
US12377096B2 (en) 2025-08-05
CA3132319A1 (en) 2020-09-10
AU2020232246A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN107249591B (zh) 固体药物配制品及其制备方法
EP3086787B1 (en) Pharmaceutical combinations
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
EP2540318B1 (en) Sustained-release solid preparation for oral use
US20210299169A1 (en) Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage
JP7801408B2 (ja) レボケトコナゾールによる疾患の処置方法
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
AU5198301A (en) The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
EP2762141A1 (en) Drug for the treatment of allergic rhinitis comprising pgd2 antagonist and histamine antagonist
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
SG184176A1 (en) Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
US20240374600A1 (en) Methods and compositions for treating cancer
EP3025711B1 (en) Medicine for preventing or treating hypertension
JP2022536669A5 (https=)
HK40062461A (en) Methods of treating disease with levoketoconazole
US20210220300A1 (en) Methods of treating disease with dichlorphenamide
US20260041677A1 (en) Compositions and methods for treating adenoid cystic carcinoma
US20240180874A1 (en) Improved treatment of ovarian cancer with nirogacestat
WO2026044127A1 (en) Administration of cyp3a inhibitors in the treatment of cancer
JP2025540124A (ja) 乳がんを治療する方法
CA2956315A1 (en) Steroid-free disease management

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241016

R150 Certificate of patent or registration of utility model

Ref document number: 7574204

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150